Technology Holdings is pleased to announce that it has acted as the exclusive financial advisor to Across Health on its strategic sale to Precision Value & Health, a division of Precision Medicine Group, backed by The Blackstone Group.
From our first meeting, Technology Holdings recognized our unique proposition as a specialist strategic consultancy, providing evidence-based omnichannel customer engagement and digital transformation services and products to life sciences companies. TH ran a structured and highly professional sale process, securing a total of 12 offers from buyers globally, leveraging their extensive buyer relationships and deep expertise in the digital transformation and life sciences sectors. As we navigated through Covid-19, TH ensured that we capitalized on our unique proposition, selected the right strategic partner and secured a premium valuation for Across Health. We’d like to thank the TH team for their effort, resilience and for managing the heavy lifting at every step of the process, from preparing compelling material through to due diligence process management and negotiation. The level of advice provided from start to finish was of the highest calibre and was instrumental in ensuring that we found the ideal partner in Precision Medicine Group to continue our growth journey. We would certainly recommend Technology Holdings to any company considering a sale - their deep sector expertise and knowledge of the buyer landscape is truly unparalleled.
Founded in 2008 and headquartered in Belgium, Across Health is a global omnichannel engagement leader, focused on providing analytical and evidence-based frameworks for commercial strategy, execution and resource optimization to the leading life sciences companies. The foundation of Across Health’s solutions is their market leading Navigator365 product suite, a SaaS-based analytical tool for omnichannel launch planning, campaign strategy formulation, resource allocation, and impact measurement, which more than 40 pharmaceutical brands rely on for omnichannel planning and resource allocation. These innovative products are complemented by decades of deep industry consulting expertise that helps clients develop a measurably effective omnichannel strategy – for launch, and throughout the entire commercialization life cycle.
Carolyn Morgan, Precision Value & Health’s EVP, Physician and Patient Engagement, said “The cultural fit between our teams was immediate and collaboration began almost instinctively. Across Health is built around a family of proprietary products that helps clients optimize their go-to-market strategy and resources using a uniquely actionable analytical framework. Their expertise, plus the Navigator365, allows us to step into a new level of evidence-based omnichannel customer engagement that will drive better decision making with, and even greater success for our clients.”
Fonny Schenck, Founder and CEO, Across Health said, “For years we have honed our pragmatic, evidence-based, end-to-end products and consultative insights to accelerate digital transformation and optimize the omnichannel go-to-market model for leading life sciences companies. We are excited to team up with Precision Value & Health, so that we can better serve our current and future clients across the globe with a complete range of offerings. Technology Holdings was instrumental in the success of the transaction, and ran a structured and highly professional sale process, securing a total of 12 offers from buyers globally, ensuring that we found the ideal partner in Precision Value & Health. Their deep sector expertise in digital transformation and life sciences is unparalleled.”
Vivek Subramanyam, Founder and CEO of Technology Holdings said “It gives us immense pleasure to close this truly game changing strategic transaction in life sciences and omnichannel digital transformation. Fonny and his team have built a data driven innovative global omnichannel and digital transformation leader. Closing this transaction and securing the best possible outcome for our client, despite the backdrop of Covid-19, is a testament to our deep life sciences and digital transformation expertise and extensive global buyer relationships.”